Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS stud

8 days ago

The TACHIS study evaluated eptinezumab's effectiveness and tolerability in routine clinical practice for migraine prevention.
Eptinezumab is the only intravenous anti-CGRP monoclonal antibody approved for migraine prevention.
The study included 128 patients (82% female, 82% chronic migraine) followed for 24 weeks.
MMDs decreased by 5.7 days at week 12 and 6.9 days at week 24 (p < 0.001).
≥50% response rates were 43.8% at week 12 and 48.2% at week 24.
Over 40% of patients achieved optimal or modest migraine control.
CGRP therapy-naïve patients experienced greater benefits, though non-naïve patients also improved.
Female sex and chronic migraine diagnosis were independently associated with response at 12 weeks.
Adverse events were infrequent (4.7%) and mild, with no discontinuations due to safety concerns.
Eptinezumab demonstrated effectiveness and tolerability in real-world patients with prior treatment failures.

Hasty Briefsbeta